Ash Publications

BLOOD COMMENTARIES REVIEW ARTICLE Heparan sulfates and heparan sulfate proteoglycans in hematopoiesis CLINICAL TRIALS AND OBSERVATIONS Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies Clinical Trials & Observations IMMUNOBIOLOGY AND IMMUNOTHERAPY Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells LYMPHOID NEOPLASIA Loss of GABARAP mediates resistance to immunogenic chemotherapy in...

Research Article | Archana Ramgopal, Erica Braverman, Lee-Kai Sun, Darlene Monlish, Christopher James Wittmann, Felicia Kemp, Mengtao Qin, Manda J Ramsey, Richard Thomas Cattley, William Hawse, Craig Byersdorfer; AMPK Drives both Glycolytic and Oxidative Metabolism in Murine and Human T Cells During Graft-versus-host Disease. Blood Adv 2024; bloodadvances.2023010740. doi: https://doi.org/10.1182/bloodadvances.2023010740 Download citation file:

Al Tabaa Y, Casasnovas RO, Baillet C, et al. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Adv. 2023;7(14):3735-3738.. 2024; 8 (12): 3225. doi: https://doi.org/10.1182/bloodadvances.2024013536 Download citation file:

Skip Nav Destination July 2024 You do not currently have access to this content. Advertisement intended for health care professionals Connect with us: CURRENT ISSUE June 2024 Advertisement intended for health care professionals

JAK2-V617F alone or together with additional somatic mutations is found in the majority of patients with myeloproliferative neoplasm (MPN).1 The presence of additional mutations correlates with worse outcome,2,3 and "high molecular risk" mutations with a strong negative impact on outcome have been identified.4 Although mutations in DNMT3A are relatively frequent in patients with MPN (∼5%-6%),5 and their frequencies are increased in patients with MPN who progress to acute myeloid leukemia...

Neutrophils are the first migrating responders to sterile and infectious inflammation and act in a powerful but nonspecific fashion to kill a wide variety of pathogens. It is now apparent that they can also act in a highly discriminating fashion; this is particularly evident in their interactions with other cells of the immune system.

Subjects: In this issue of Blood, Vallée and colleagues have distinguished 2 classes of WAS variants in patients with Wiskott-Aldrich syndrome (WAS, Online Mendelian Inheritance of Man #301000), which provide, for the first time, a molecular biomarker of disease severity and outcome.1 WAS was first described in 1937 in Germany by Wiskott2 and later in the United States by Aldrich et al3 as a clinical entity comprised of thrombocytopenia, eczema, recurrent infections, autoimmunity, and cancer...

Subjects: In this issue of Blood, Klein et al report the first genetically engineered mouse model of natural killer (NK)-cell leukemia, unlocking in vivo preclinical investigation of disease biology and therapeutics in NK-cell malignancies.1 NK-cell malignancies include NK-cell large granular lymphocytic leukemia (NK-LGLL), also known as chronic lymphoproliferative disorder of NK cells, as well as the more aggressive extranodal NK/T-cell lymphoma (ENKTL) and aggressive NK-cell leukemia (ANKL)...

Metabolic tumor volume (MTV) assessed using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography, a measure of tumor burden, is a promising prognostic indicator in large B-cell lymphoma (LBCL). This exploratory analysis evaluated relationships between baseline MTV (categorized as low [median or less] vs high [greater than median]) and clinical outcomes in the phase 3 ZUMA-7 study (NCT03391466).